Best ADC (Antibody-Drug Conjugate) CDMOs in Asia

← All ADC CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

For Asia-manufactured adc (antibody-drug conjugate) programs, WuXi Biologics, Piramal Pharma Solutions, and AGC Biologics lead CDMO Signal's ranking of adc (antibody-drug conjugate) CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 10 scored adc (antibody-drug conjugate) CDMOs to 4 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.

Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 2 NAI (no action), 5 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), UNITED KINGDOM (8), Germany (4), INDIA (4), India (3).

Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	WB2 WuXi Biologics Shanghai, CN · Wuxi, CN	83.7	100.0	0 insp · 4 GMP	—	0 programs
2	PR Piramal Pharma Solutions Lexington, KY · Riverview, MI · Ahmedabad, IN	83.6	95.7	5 insp · 13 GMP	—	0 programs
3	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	2 insp · 23 GMP	Available	2 programs
4	SB Samsung Biologics Incheon, South Korea, Rockville, Maryland, USA	61.5	—	—	Available	0 programs
—	WuXi XDC Shanghai, China	Profiled	—	—	—	0 programs
—	Altruist Biologics Suzhou, China	Profiled	—	—	Available	0 programs
—	Meiji Seika Pharmatech Co., Ltd. Odawara, Japan	Profiled	—	—	—	0 programs
—	EirGenix Zhubei City, Taiwan	Profiled	—	—	—	0 programs
—	Sai Life Sciences Hyderabad, India	Profiled	—	—	—	0 programs
—	BE Biosol (formerly SGI Pharma / Biological E, Samirpet) Hyderabad, India	Profiled	—	—	—	0 programs
—	AsymBio Shanghai, China	Profiled	—	—	—	0 programs
—	Aarti Pharmalabs Limited Mumbai, India	Profiled	—	—	—	0 programs
—	Novelty Nobility Inc. Seoul, South Korea	Profiled	—	—	—	0 programs
—	Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.) Hangzhou, China	Profiled	—	—	—	0 programs
—	Chime Biologics Wuhan, China	Profiled	—	—	—	0 programs
—	Asymchem / AsymBio Morrisville, NC (US HQ); Tianjin, China (primary manufacturing)	Profiled	—	—	—	0 programs
—	Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) Lianyungang, China	Profiled	—	—	—	0 programs
—	WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.) Shanghai, China	Profiled	—	—	—	0 programs
—	Laurus Labs Hyderabad, India	Profiled	—	—	—	0 programs
—	Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma) Tokyo, Japan	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a ADC (Antibody-Drug Conjugate) CDMO

HPAPI containment

Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.

Linker-payload chemistry on file

Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.

Commercial bioconjugation track record

Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.

Integrated DS + DP

Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

ADC (Antibody-Drug Conjugate) CDMOs — Frequently Asked Questions

Who are the top ADC (Antibody-Drug Conjugate) CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked ADC (Antibody-Drug Conjugate) CDMOs include WuXi Biologics, Piramal Pharma Solutions, AGC Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?

CDMO Signal tracks 2 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 40 EMA/MHRA GMP certificates across the group.

What's the difference between an ADC CDMO and a biologics CDMO?

A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.

Which CDMOs have made commercially-approved ADCs?

Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.

What HPAPI containment level should an ADC CDMO have?

OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.

Related modalities

Biologics / mAb CDMOs Oligonucleotide / ASO CDMOs Recombinant Proteins CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins